Funding for this research was provided by:
American Association for Cancer Research (19-40-12-PETE)
National Cancer Institute (P20CA252728)
National Cancer Institute (R01CA159036)
National Cancer Institute (U01CA250186)
Received: 26 October 2021
Accepted: 14 October 2022
First Online: 27 October 2022
: The study described in this manuscript conformed to the Declaration of Helsinki and was approved by the institutional review board of the NYU School of Medicine, and all participants provided written informed consent (IRB study number: 8896).
: Not applicable.
: BAP received a funded fellowship from the American Association for Cancer Research and AstraZeneca. All other authors declare no competing interests.